The Institute for Gene Therapies is a nonprofit advocacy group based in Washington, D.C. It lobbies Congress on gene therapy policy, especially how these treatments are regulated and paid for under Medicare and Medicaid, and on newborn screening and FDA funding. Its filings show work on reimbursement issues and the MVP Act (H.R. 7389).
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DAVID RUDLOFF
The latest disclosures for this client.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q2JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
LAURA KEMPER
JEFFREY J. KIMBELL & ASSOCIATES, INC.
mr JEFFREY J KIMBELL
JEFFREY J. KIMBELL & ASSOCIATES, INC.
mr KENNETH LEE HODGE
JEFFREY J. KIMBELL & ASSOCIATES, INC.
JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q3JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q2JEFFREY J. KIMBELL & ASSOCIATES, INC.
Q1